How do inhaled bronchodilators work?

E C Smith; A H Kendrick

Home/Archive/PubMed

PubMed · 8483961

How do inhaled bronchodilators work?

E C Smith·A H Kendrick

View original source ↗Export metadata ↓

Abstract

1. Beta-agonists affect bronchodilation of the airways by their action on the bronchial smooth muscles. 2. Anticholinergic drugs affect bronchodilation of the airways by blocking the effect of acetylcholine and its bronchoconstrictor action. 3. Receptors are protein molecules found in cell membranes; they can selectively bind to messenger molecules and transduce a chemical signal into a response in a target cell.

Explore related subjects

Acetylcholine Administration, Inhalation Bronchodilator Agents Humans Journal Article

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

E C Smith, A H Kendrick. 1993. How do inhaled bronchodilators work?. https://pubmed.ncbi.nlm.nih.gov/8483961/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1998

A leucine-based motif mediates the endocytosis of vesicular monoamine and acetylcholine transporters.

Specific transport proteins mediate the packaging of neurotransmitters into secretory vesicles and consequently require targeting to the appropriate intracellular compartment. To identify residues in the neuron-specific vesicular monoamine transporter (VMAT2) responsible for endocytosis, we examined the effect of amino (NH2-) and carboxyl (COOH-)-terminal mutations on steady state distribution and internalization. Deletion of a critical COOH-terminal domain sequence (AKEEKMAIL) results in accumulation of VMAT2 at the plasma membrane and a 50% reduction in endocytosis. Site-directed mutagenesis shows that replacement of the isoleucine-leucine pair within this sequence by alanine-alanine alone reduces endocytosis by 50% relative to wild type VMAT2. Furthermore, the KEEKMAIL sequence functions as an internalization signal when transferred to the plasma membrane protein Tac, and the mutation of the isoleucine-leucine pair also abolishes internalization of this protein. The closely related vesicular acetylcholine transporter (VAChT) contains a similar di-leucine sequence within the cytoplasmic COOH-terminal domain that when mutated results in accumulation of VAChT at the plasma membrane. The VAChT di-leucine sequence also confers internalization when appended to two other proteins and in one of these chimeras, conversion of the di-leucine sequence to di-alanine reduces the internalization rate by 50%. Both VMAT2 and VAChT thus use leucine-based signals for efficient endocytosis and as such are the first synaptic vesicle proteins known to use this motif for trafficking.

Acetylcholine↗

PubMed1998

Effect of atherosclerosis on endothelium-dependent inhibition of platelet activation in humans.

BACKGROUND: We investigated whether luminal release of nitric oxide (NO) contributes to inhibition of platelet activation and whether these effects are reduced in patients with atherosclerosis. METHODS AND RESULTS: Femoral blood flow velocity and ex vivo whole blood platelet aggregation by impedance aggregometry were measured in femoral venous blood during femoral arterial infusion of acetylcholine (ACh; 30 microg/min) in 30 patients, 19 of whom had angiographic atherosclerosis. Measurements were repeated with sodium nitroprusside (40 microg/min), L-arginine (160 micromol/min), and N(G)-monomethyl-L-arginine (L-NMMA; 16 micromol/min). There was significant inhibition of collagen-induced platelet aggregation with ACh (45+/-9.5% lower, P<0.001), and this inhibition was greater in patients without atherosclerosis (68.7+/-10.4% reduction) than in those with atherosclerosis (32.5+/-8.1%, P=0.04). The magnitude of inhibition correlated with vasodilation with ACh, indicating an association between the smooth muscle and antiplatelet effects of endothelium-dependent stimulation. Neither L-NMMA nor sodium nitroprusside altered platelet aggregation. L-Arginine inhibited platelet aggregation equally in vitro (34+/-8% reduction, P<0.01) and in vivo (37+/-13% reduction, P<0.01). CONCLUSIONS: Stimulation of NO release into the vascular lumen with ACh inhibits platelet aggregation, an effect that is attenuated in patients with atherosclerosis and endothelial dysfunction. Basal NO release does not appear to contribute to platelet passivation in vivo. L-Arginine inhibited platelet aggregation by its direct action on platelets. These findings provide a pathophysiological basis for the observed increase in thrombotic events in atherosclerosis. Use of L-arginine and other strategies to improve endothelial NO activity may impact favorably on thrombotic events in atherosclerosis.

Acetylcholine↗

PubMed1998

Galanin in the hypothalamus raises dopamine and lowers acetylcholine release in the nucleus accumbens: a possible mechanism for hypothalamic initiation of feeding behavior.

Rats were prepared with two implanted guide shafts, one for microdialysis to measure extracellular dopamine (DA) and acetylcholine (ACh) in the posterior, medial nucleus accumbens (NAc), and the other for microinjection of galanin, neuropeptide Y or saline in the hypothalamic paraventricular nucleus (PVN). There was an increase in DA release and a decrease in ACh in the NAc following microinjections of galanin into the PVN. The effect was observed only in rats for which identical galanin injections induced feeding in separate tests. Ringer injections had no effects. Unlike galanin, neuropeptide Y in the PVN induced eating without altering DA/ACh; whereas earlier results showed that norepinephrine in the PVN works like galanin. These results suggest that galanin initiates feeding, in part, by activating the mesolimbic DA system and suppressing intrinsic cholinergic activity in the NAc. This may prime instrumental behavior with DA while disinhibiting behavior by lowering ACh.

Acetylcholine↗